Table 2 Summary of mTOR inhibitors in combination with other antitumor drugs
From: mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
mTOR inhibitors | Combined drug | Applied tumor | The effect | References |
|---|---|---|---|---|
Everolimus | VEGF inhibitor lenvatinib | RCC | Progression-free survival is significantly extended compared to using them separately | Motzer et al. [75] |
PF-384 | MEK inhibitor PD-901 | HNSCC | They inhibit the production of IL-8 and VEGF and the activation of NF-κB and AP-1 | Mohan et al. [76] |
AZD8055 | HSP90 inhibitor AUY922 | Breast cancer | AZD8055 inhibits the upregulation of HSP70 and HSP27 induced by AUY922, while AUY922 blocks the activation of PI3K/Akt induced by AZD805 | Chen et al. [78] |
Rapamycin | AR inhibitor enzalutamide | HCC | Rapamycin inhibits the AKT/mTOR signaling pathway activated by enzalutamide, while enzalutamide inhibits the up-regulation of AR expression caused by rapamycin | Zhang et al. [77] |
Everolimus | Carboplatin and paclitaxel | LCNEC | They improve the overall response rate and disease control rate | Christopoulos et al. [79] |
AZD2014 | Wee1 inhibitor AZD1775 | NSCLC | AZD2014 enhances the effect of AZD1775 by reducing cyclin D1 to enhance DNA damage | Hai et al. [80] |